CRISPR Therapeutics AG CRSP NASDAQ

CRISPR Therapeutics AG (CRSP) has shown exceptional revenue growth over the past 3 years, expanding from $436,000 to $4M (average +28286.1%/yr). The company reported a net loss of $582M in its most recent fiscal year, with earnings trending at -40.3%/yr. The net profit margin is -16569.8%, which is negative. The company has not reported a profit in any of the last 4 years tracked. The gross margin is -6537% (low), with a +18649.7pp trend over the period. With a $5B market cap and MOAT composite score of 27/100, the company has a low competitive position.

Criteria proven by this page:

• GROWTH (58/100, Partial) — growth is present but not consistently above 5% across both metrics
• PAST (0/100, Fail) — the company has frequently reported losses. Looking at the full 12-year history, the company was profitable in 2 of 12 years — a mixed long-term record
• INCOME (10/100, Fail) — the company is currently operating at a loss
• MOAT (27/100, Fail) — limited competitive moat based on margins and scale

Overall SharesGrow Score: 48/100 with 2/7 criteria passed.